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Prior studies have shown that patients are reluctant to accept donor-specific risks, and transplant professionals lack an
effective and time-efficient means of obtaining informed consent. We designed and pilot-tested a Web-based patient deci-
sion aid (DA) on organ quality. The DA was administered to 53 liver transplant candidates (median Model for End-Stage
Liver Disease score514, range57-26), and they took a mean of 15 minutes to complete it. Questions about knowledge
and attitudes were asked before and after the DA. Subjects’ knowledge improved, with 53% and 60% correctly answering
questions about hepatitis B virus and human immunodeficiency virus transmission before the DA and 94% and 100%,
respectively, correctly answering them afterward (P<0.001). The accuracy of mortality prediction also improved from a
mean 3-month mortality estimate of 22% before the DA to 12% afterward (P< 0.001). After the DA, subjects felt that it was
more likely that they might be offered a less-than-perfect liver (P50.001), and they were more likely to consider accepting
such a liver (P< 0.001). In conclusion, implementing a Web-based patient DA is feasible and improves knowledge among
liver transplant candidates. The use of this tool may decrease candidates’ reluctance to accept extended criteria organs.
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Not all liver allografts are of equal quality. We conceptu-
alize organ quality as an overarching concept with 2 pri-
mary subdomains: risk of graft failure and risk of
disease transmission. Donor characteristics such as
age, cause of death, steatosis, and ischemia time can
make the difference between 20% and 40% rates of graft
failure within the first 3 years after transplantation.1
Furthermore, the quality of available organs appears
likely to worsen in the coming years. The donor pool is
aging, more donors have experienced stroke as the
cause of brain death, and the use of donors after cardiac
death is increasing.2 Thus, issues of organ quality are
increasingly relevant for every liver transplant candidate.
Although organ quality is a spectrum, the term
extended criteria donor organ is used to refer to an
organ with a higher-than-average risk of graft failure
or disease transmission. Each time that an extended
criteria donor organ offer is made, the patient and the
physician are faced with a difficult choice: to accept
the offer or to wait in the hope that a better liver will
come along. For patients with end-stage liver disease,
this decision could mean the difference between life
and death. For physicians, this decision is fraught
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with uncertainty, and communicating the various
risks to the patient can be challenging.3,4 Yet, it is
critical that patients understand this information
because our prior work has demonstrated that
patients want to be involved in the decision about
what type of organ they receive: 83% of those sur-
veyed indicated that they would prefer an equal or
dominant role in the decision.5
Ideally, discussions about organ quality should
begin during the transplant evaluation so that the
candidate is prepared for the potentially middle-of-
the-night decision of whether or not to accept an
available liver. However, this is easier said than done
at a busy transplant clinic with other competing pri-
orities. Our previous work highlighted not only
patients’ desire for involvement in decision making
but also their poor understanding of issues of organ
quality and preconceived notions and biases about
the topic.5 Transplant professionals are in need of a
tool to educate patients and satisfy requirements for
informed consent in a time-efficient manner. There-
fore, we designed and pilot-tested a Web-based
patient educational tool and decision aid (DA) about
liver transplant organ quality. Our goal was to provide
patients with information that can supplement their
discussions with their physicians and to test whether
receiving this information would make patients more
informed about the risks and benefits or change their
attitudes about accepting an extended criteria liver.
PATIENTS AND METHODS
Design of the DA
The design of the DA was based primarily on results
from our prior study4 and a study by Rodrigue et al.,5
who found that the majority of liver transplant candi-
dates (1) assume that any organ offered to them will
be of good quality, (2) do not understand the inherent
tradeoff between organ availability and organ quality,
and (3) are resistant to accepting anything but a very
high quality organ. The template was written by the
first author (M.L.V.) and revised by a health writer
with expertise in health literacy. Design features were
also based on state-of-the-art knowledge about best
practices in patient DAs, with input from experts in
graphic design, human factors engineering, and deci-
sion psychology. Examples of these best practices
include the use of absolute risks, pictographs, plain
language, and tailoring.3,7
The beginning of the DA is focused on addressing
knowledge gaps (eg, the definition, risk factors, and
health implications of graft failure). Because the liter-
ature suggests that the primary determinant of
whether or not to accept an organ should be the can-
didate’s risk of dying while he or she is waiting,8 we
present the 3-month wait-list mortality risk in a
graphical format (Fig. 1). This risk is tailored to the
individual candidate and is based on his or her most
recent Model for End-Stage Liver Disease (MELD)
Figure 1. Presentation of the waiting-list mortality risk based on the patient’s MELD score.
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score (which was entered into the DA by a research
coordinator to ensure the accuracy of the input).9
This information then sets the stage for framing the
tradeoff between organ quality and organ availability
and leads to an interactive organ offer exercise. In
this exercise, the patient is able to adjust his or her
risk tolerance for organ quality and see how this toler-
ance affects organ availability. As shown in Fig. 2, the
initial settings are tailored to the individual patient on
the basis of the most recent MELD score.8 This is
done because our prior work and a long history in
psychology have demonstrated that patients are anch-
ored to the initial value that they see.10 Finally, the
DA concludes with a discussion about the risks of dis-
ease transmission from organ transplantation. The
DA recommends that all patients accept Centers for
Disease Control and Prevention (CDC) increased-risk
organs as well as organs from donors with hepatitis B
core positivity. The rationale for this recommendation
is that any patient sick enough to justify the 5% to
10% 1-year risk of perioperative mortality associated
with liver transplantation should be willing to accept
the numerically much smaller risk of disease
transmission.11,12
Preliminary usability testing was conducted with
clinic staff (nurses, transplant hepatologists, and sur-
geons) and 5 patients, and we revised the program to
reflect their comments. The pilot version of the DA
can be seen online.13
Study Design
The aims of this pilot study were to demonstrate that
the DA (1) is usable by liver transplant candidates, (2)
increases patients’ knowledge, and (3) decreases can-
didates’ reluctance to accept organs of less-than-
perfect quality.
Approval for the performance of this study was
obtained from our institutional review board. Adult
patients (18 years old or older) on the waiting list for
liver transplantation at our center were approached at
the clinic for participation. We included only subjects
already on the waiting list, who at our center had
already undergone extensive pretransplant education,
including discussions with an attending surgeon
about organ quality. The exclusion criteria were grade
2 or worse hepatic encephalopathy (assessed during
the pre-enrollment screening of medical records and
again in person during the initial contact) and previ-
ous participation in any of our prior studies on organ
quality. We also excluded candidates listed primarily
for MELD exceptions such as hepatocellular carci-
noma in order to simplify the interpretation of the
results for this initial pilot test. After informed con-
sent was obtained, the DA was administered in 1 of 2
formats according to patient preference. Patients
could either use an iPad provided at the clinic or
access the DA on a secure Web site from their home
computer.
Figure 2. Risk tolerance exercise used to emphasize the tradeoff between organ quality and organ availability.
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Outcome Measures
Usability measures, including the completion rate and
the time spent per subject, were calculated from the
Web site. The interactive features of the DA provided
an additional opportunity for data gathering: partici-
pants provided their final risk tolerance after the
organ offer exercise and also indicated whether they
would be willing to accept CDC increased-risk and/or
hepatitis B core–positive organs. Those who would not
accept CDC increased-risk or hepatitis B core–positive
organs were asked to provide open-ended comments
about their reasons for not accepting them. Finally,
the impact of the DA on knowledge and attitudes was
assessed with a pre/post design, with survey items
administered immediately before and after the DA.
The full version of this survey can be seen in the sup-
porting information.
Knowledge Questions
The following knowledge questions were used:
1. Out of 100 people with the same severity of liver
disease as you have, how many do you think die
during a 3-month period on the waiting list?
2. True or false: It is possible to get human immu-
nodeficiency virus (HIV) from a liver transplant,
even if the donor tested negative.
3. True or false: If the donor has been exposed to
hepatitis B in the past, the liver is not usable.
Attitude Questions
Attitudes were measured with the following questions:
1. Imagine that an organ becomes available. How
likely do you think the surgeon will be to offer
you this organ if it is less than perfect?
2. Would you ever consider accepting a less-than-
perfect liver?
3. How confident do you feel in your ability to make
a decision about whether to accept or turn down
a liver?
4. How confident do you feel in your ability to dis-
cuss these issues with your doctor?
Statistical Analysis
Statistical analysis was performed with a matched t
test for attitudes measured on a 6-point scale as well
as waiting-list mortality estimates before and after the
DA. McNemar’s test was used to compare true/false
and yes/no questions before and after the DA. The
primary outcome measure was the attitude toward
accepting extended criteria organs. On the basis of
our prior data, we a priori hypothesized a 20%
improvement in the likelihood of accepting a less-
than-perfect liver. Thus, a sample size of 53 subjects
would provide 90% power to detect this difference
with a 2-sided t test for matched pairs with a repeated
measures correlation of 0.3.
RESULTS
Participant Characteristics
Seventy-two liver transplant candidates on the waiting
list were approached for participation. Fifty-six (78%)
were enrolled, and 53 of those candidates (95%) com-
pleted the study. The 3 candidates who did not com-
plete the study had begun the DA in the waiting room
before their visit and chose to leave the clinic immedi-
ately afterward without completing it. The clinical and
demographic characteristics of the 16 patients who
chose not to participate appeared identical to those of
the participants (data not shown). Demographic and
clinical characteristics of the participants are shown
in Table 1. Fifty-one of the 53 participants (96%) com-
pleted the DA on an iPad at the clinic, and 2 (4%)
completed the DA online from home. The time spent
taking the DA ranged from 7 to 28 minutes, with par-
ticipants spending an average of 15 minutes.
Risk Preferences
After going through the organ offer exercise, partici-
pants were willing to accept liver allografts with a
median risk of graft failure of 28% 3 years after trans-
plantation. Participants who spent more time on the
DA tended to be more risk-averse; each extra minute
was associated with a 0.4% lower tolerance of graft
failure risk (r250.15, P50.004). Seventy-nine percent
of the participants were willing to accept CDC
increased-risk organs, and 76% were willing to accept
hepatitis B core–positive organs. Sixteen patients
were unwilling to accept 1 or both of these forms of
an increased risk of disease transmission, and the
reasons that they provided included the following: the
feeling that they were healthy enough to wait for a
higher quality organ (n56), concerns about the cost
and side effects of the pills required to receive a hepa-
titis B core–positive organ (n53), the desire to confer
with their physician (n51), not wanting to risk infect-
ing anyone else (n52), and simply not being
TABLE 1. Demographic Characteristics of 53
Wait-Listed Patients
Median age (years) 56 (20-67)
Male sex (%) 55
Race/ethnicity (%)
White 87
Black 4
Hispanic 7
Other 2
Median laboratory MELD score 14 (7-26)
Primary diagnosis (%)
Alcohol 15
Viral 32
Cryptogenic/fatty liver 23
Other 30
NOTE: Ranges are shown in parentheses.
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comfortable with any risk/wishing to have a liver of
the best quality possible (n54).
Impact of the DA on Knowledge and Attitudes
Survey responses after the DA demonstrated improve-
ments in knowledge, as shown in Table 2. When they
were asked if HIV could be transmitted via organ
transplantation, 60% answered yes (true) correctly
before the DA, and 100% answered correctly after-
ward. Similarly, 53% responded correctly before the
DA that hepatitis B core–positive organs could be
used, whereas 94% responded correctly to this ques-
tion after the DA. The accuracy of mortality predic-
tions also improved, although not in the direction that
we had anticipated. We had hypothesized that under-
estimation of waiting-list mortality risk might be a fac-
tor in candidates’ reluctance to accept extended
criteria organs. However, the subjects initially esti-
mated a mean 3-month mortality estimate of 22%,
which was inappropriately high for this group, which
had a median MELD score of 14. After the DA, the
mean estimate decreased to 12% (P<0.001).
Attitudes about organ quality were also influenced by
the DA, as shown in Table 2. After the DA, subjects felt
it more likely that they might be offered a less-than-
perfect liver (P50.001), and they were more likely to
consider accepting such a liver (P<0.001). These dif-
ferences appeared similar across MELD scores. For
example, among patients with MELD scores<15
(n530), the willingness to accept a suboptimal liver
improved from 3.7 to 4.9 (P<0.001), whereas this will-
ingness improved from 3.2 to 4.2 (P50.03) among par-
ticipants with MELD scores of 15 or greater (n523).
Subjects’ confidence in their ability to make the deci-
sion or discuss it with the surgeon did not change.
DISCUSSION
This pilot study has demonstrated that a patient DA
can improve liver transplant candidates’ knowledge
about organ quality and decrease candidates’ reluc-
tance to accept extended criteria organs. The DA is
intended not to replace patient-physician discussions
but rather to augment them. Organ quality is a com-
plex topic, and when a physician is counseling a
patient, it could be useful for the patient to have
already gained some knowledge and to have spent
time considering the risks and benefits. For example,
despite prior explicit counseling about CDC
increased-risk organs at the clinic, 40% of the
patients in this pilot study did not realize before they
used the DA that they could get HIV from a liver
transplant.
This study also extends our prior work in under-
standing how patients think about organ quality. It
confirms that many patients hold a preconceived bias
against donor-specific risks. However, contrary to our
hypothesis, an underestimation of mortality risk was
not a factor influencing this bias. Conversely, most
patients overestimated their mortality risk. Further-
more, despite extensive education and a strong rec-
ommendation to accept CDC increased-risk and
hepatitis B core–positive organs, 21% and 24% of the
subjects remained unwilling to do so. We conclude
that education can mitigate but not completely elimi-
nate patients’ unwillingness to accept donor-specific
risks, even when doing so might improve their chan-
ces for survival. This conclusion, along with strong
patient preferences for involvement, supports the
importance of comprehensive informed consent in
organ acceptance decisions.
It is unclear why the DA did not lead to improve-
ments in subjects’ confidence in their ability to make
the decision or discuss it with the surgeon. We were
able to conduct brief follow-up interviews with 5 sub-
jects who subsequently underwent transplantation,
and they all expressed that the DA was helpful to
them at the time of the organ offer. We speculate that
many patients may not have fully appreciated the
complexity of the subject before they completed the
DA. Additionally, a certain lack of confidence may be
entirely appropriate for such high-risk, low-certainty
decisions.
TABLE 2. Survey Responses Before and After Use of the DA
Before DA After DA P Value
Knowledge
3-month mortality risk 22% risk of death 12% risk of death <0.001
Possible to get HIV from a transplant 60% correct 100% correct *
Hepatitis B virus donor not usable 53% correct 94% correct <0.001
Attitudes†
Likelihood that surgeon will offer you a less-than-perfect organ 3.74 4.40 0.001
Willingness to consider a less-than-perfect organ 3.53 4.60 <0.001
Confidence in ability to decide 4.72 4.98 0.12
Confidence in ability to discuss with physician 5.66 5.58 0.10
*The P value could not be calculated because there were 0 incorrect responses after the DA was used. If 1 subject had
responded incorrectly, the difference between pre-DA and post-DA results would have been significant at P<0.001.
†Attitudes were graded on a 6-point Likert scale.
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It is important to emphasize that this was a small
pilot study at a single center, and the findings may not
apply to other patient populations. The limited number
of questions about patient knowledge prevents a
detailed investigation into domains of knowledge. Fur-
thermore, pre/post study designs tend to exaggerate
effect sizes in comparison with randomized trials.
Finally, this pilot study assessed intermediate end-
points only. Further studies are now required before
this tool is used in clinical practice; such studies will
need to be multicenter and randomized and should
address the impact of the DA on the actual decisions
made. Future studies should also assess how patient
preferences change over time as the severity of their
liver disease changes, and they may also explore the
impact of family involvement on these decisions. Fam-
ily involvement may be particularly important for
patients with significant encephalopathy, which was
an exclusion criterion for this study. However, this is a
feasibility study and suggests that this DA may ulti-
mately serve as a useful educational tool.
In summary, this DA is usable by transplant candi-
dates, improves their knowledge about organ quality,
and decreases their reluctance to accept extended cri-
teria organs. If validated in future studies, this could
be a useful tool for the transplant community to sat-
isfy ethical requirements to inform patients about
organ quality issues in a time-efficient manner.
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